{'fraction_non_alphanumeric': 0.03681710213776722, 'fraction_numerical': 0.019002375296912115, 'mean_word_length': 5.853658536585366, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Biologics as a therapeutic approach for a Th17‐mediated severe dermatitis in skin barrier disorders

Biologics are a promising treatment for immune-mediated diseases in which the predominant pathogenic pathway is targeted. The use of biologics therapyfor epidermal barrier function-impairingpathologiesfollows 3 strategies: tapering ofT helper (Th) 2responses; neutralization of non-type 2 pathways such as Th17; or blockade of acute phase reactions such as those driven by interleukin (IL)-6(1). Initially, the treatment of eczematous disorders focused on the Th2 response without considering the key contribution of Th17 cells.However,recent work by Hernández-Martínet al. (2) reports the successful treatment ofa 9-month-oldpatientwith severe dermatitis, allergies, and metabolic wasting (SAM)-like syndrome via targeting the Th17 pathway.